Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome
Source: Cochrane
Area: Evidence > Disease Focused Reviews
Background
Fibromyalgia syndrome (FMS) is a clinically well-defined chronic condition of unknown etiology characterized by chronic widespread pain that often co-exists with sleep disturbances, cognitive dysfunction and fatigue. Patients often report high disability levels and poor quality of life (QOL). Drug therapy focuses on reducing key symptoms and improving quality of life.
Objectives
To assess the benefits and harms of serotonin and noradrenaline reuptake inhibitors (SNRIs) compared with placebo for treating FMS symptoms in adults.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), (The Cochrane Library 2012, Issue 9), MEDLINE (1966 to September 2012), EMBASE (1980 to September 2012), www.clinicalstudyresults.org (U.S.-marketed pharmaceuticals) (to September 2012) and www.clinicaltrials.gov (to September 2012) for published and ongoing trials and examined the reference lists of reviewed ...
Source: NeLM - Disease Focused Reviews - Category: Internal Medicine Source Type: news
More News: Chronic Pain | Databases & Libraries | Disability | Fibromyalgia | Internal Medicine | Pain | Sleep Disorders | Sleep Medicine